Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Artesunate-amodiaquine-methylene for Malaria Treatment in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 6-59 months old children (male and female)~* Weight ≥ 6kg~* Uncomplicated malaria caused by P. falciparum~* Asexual parasites ≥ 2 000/µl and ≤ 200 000/µl~* Axillary temperature ≥ 37.5°C or a history of fever during last 24 hours~* Burkinabe nationality~* Permanent residence in the study area with no intention of leaving during the surveillance period~* Informed consent~Exclusion Criteria:~* Severe malaria (WHO 2000)~* Vomiting (3 or more within 24 hours before the visit)~* Any apparent significant disease, including severe malnutrition~* A history of a previous, significant adverse reaction to either of the study drugs~* Anaemia (haemoglobin \< 7 g/dl)~* Treated in the same trial before~* All modern antimalarial treatment prior to inclusion (last seven days)~* Simultaneous participation in another investigational study~* Treatment with other investigational drugs

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 59 Months
- Healthy Volunteers: f

Study Arms:
- artesunate, amodiaquine methylene blue (Type: ACTIVE_COMPARATOR): two arms, open randomized controlled study in children with uncomplicated falciparum malaria in Burkina Faso. Intervention: artesunate (AS) - amodiaquine (AQ) - methylene blue (MB) control: artesunate (AS) - amodiaquine (AQ)
- artesunate amodiaquine (Type: NO_INTERVENTION): The control group will receive once daily a fixed dose AS-AQ over three days.

Based on this trial design, predict the completion outcome and termination type (if applicable).